Clinical Report: Real-World Insights on Tildrakizumab for Plaque Psoriasis

Overview

This meta-analysis synthesizes data from four observational studies on tildrakizumab, demonstrating its effectiveness in diverse patient populations with moderate-to-severe plaque psoriasis. The findings indicate consistent positive outcomes across various clinical parameters, reinforcing the treatment's reliability and impact on quality of life.

Background

Tildrakizumab is an IL-23p19 inhibitor approved for adults with moderate-to-severe plaque psoriasis. Real-world data is essential to understand its effectiveness in heterogeneous patient populations, which may differ from those in randomized clinical trials. This study addresses the gap in knowledge regarding tildrakizumab's performance in specific subgroups, such as older patients and those with high body weight.

Data Highlights

Key Findings

• Tildrakizumab showed consistent effectiveness across different patient populations.
• Positive outcomes were observed in Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), Physician’s Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) at week 28.
• The treatment demonstrated a reassuring safety profile in real-world settings.
• Quality of life improvements were noted among patients receiving tildrakizumab.
• The findings support the use of tildrakizumab in diverse clinical scenarios, including older patients and those with high body weight.

Clinical Implications

Clinicians can be reassured about the reliability of tildrakizumab for treating plaque psoriasis across various patient demographics. The positive impact on quality of life highlights the importance of considering this treatment option for patients with moderate-to-severe disease.

Conclusion

The meta-analysis underscores the effectiveness and safety of tildrakizumab in real-world populations, reinforcing its role as a valuable treatment for moderate-to-severe plaque psoriasis. Further research may continue to elucidate its benefits across diverse patient profiles.

References

1. Author(s)/Org, Source, Year -- Title
2. Drug Safety, 2024 -- Evaluating the Tolerability of Ixekizumab in Chinese Adults Suffering from Moderate-to-Severe Plaque Psoriasis
3. Clinical Rheumatology, 2026 -- Assessment of Serum TWEAK Levels and Treatment Outcomes in Psoriasis and Psoriatic Arthritis
4. Journal of Gastroenterology, 2018 -- Comprehensive Review and Meta-Analysis: Effectiveness and Safety of Vedolizumab in Real-World Patients with Inflammatory Bowel Disease
5. Clinical Rheumatology — Effectiveness of Certolizumab Pegol With and Without Disease-Modifying Anti-Rheumatic Drugs Over Four Years in Patients with Psoriatic Arthritis: Findings from the RAPID-PsA Randomized Controlled Trial
6. EuroGuiDerm Guidelines
7. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials - ScienceDirect
8. Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis - PMC